RestorGenex Stock Price, News & Analysis (NASDAQ:DFFN)

$1.43 0.04 (2.88 %)
(As of 12/12/2017 09:07 AM ET)
Previous Close$1.39
Today's Range$1.38 - $1.53
52-Week Range$1.27 - $15.50
Volume249,000 shs
Average Volume313,247 shs
Market Capitalization$20.18 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.81

About RestorGenex (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.

Receive DFFN News and Ratings via Email

Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DFFN
CUSIPN/A
Phone434-220-0718

Debt

Debt-to-Equity RatioN/A
Current Ratio0.65%
Quick Ratio0.65%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book1.61

Profitability

Trailing EPS($3.83)
Net Income$-18,030,000.00
Net MarginsN/A
Return on Equity-1,949.09%
Return on Assets40.65%

Miscellaneous

Employees10
Outstanding Shares14,520,000

RestorGenex (NASDAQ:DFFN) Frequently Asked Questions

What is RestorGenex's stock symbol?

RestorGenex trades on the NASDAQ under the ticker symbol "DFFN."

When will RestorGenex make its next earnings announcement?

RestorGenex is scheduled to release their next quarterly earnings announcement on Friday, March, 30th 2018. View Earnings Estimates for RestorGenex.

Who are some of RestorGenex's key competitors?

How do I buy RestorGenex stock?

Shares of RestorGenex can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RestorGenex's stock price today?

One share of RestorGenex stock can currently be purchased for approximately $1.43.

How big of a company is RestorGenex?

RestorGenex has a market capitalization of $20.18 million. The company earns $-18,030,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis. RestorGenex employs 10 workers across the globe.

How can I contact RestorGenex?

RestorGenex's mailing address is 1317 CARLTON AVENUE SUITE 400, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected]


MarketBeat Community Rating for RestorGenex (DFFN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  21 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  39
MarketBeat's community ratings are surveys of what our community members think about RestorGenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

RestorGenex (NASDAQ:DFFN) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for RestorGenex (NASDAQ:DFFN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

RestorGenex (NASDAQ:DFFN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.43)($0.43)($0.43)
Q4 20171($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RestorGenex (NASDAQ:DFFN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RestorGenex (NASDAQ DFFN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

RestorGenex (NASDAQ DFFN) News Headlines

Source:
DateHeadline
What You Must Know About Diffusion Pharmaceuticals Inc’s (DFFN) RisksWhat You Must Know About Diffusion Pharmaceuticals Inc’s (DFFN) Risks
finance.yahoo.com - December 8 at 5:43 PM
Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity RuleDiffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule
finance.yahoo.com - November 20 at 9:16 AM
DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBMDFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM
finance.yahoo.com - November 16 at 6:27 PM
Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateDiffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 13 at 12:12 PM
RestorGenex Corp. (DFFN) to Release Quarterly Earnings on MondayRestorGenex Corp. (DFFN) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:44 AM
Todays Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion PharmaceuticalsToday's Research Reports on Stocks to Watch: Neothetics, Inc. and Diffusion Pharmaceuticals
finance.yahoo.com - October 18 at 7:14 PM
Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma MultiformeDiffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme
finance.yahoo.com - October 17 at 6:36 PM
Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%Diffusion Pharmaceuticals Inc to Initiate Phase 3 Trial in Inoperable GBM; Shares Soar 35%
finance.yahoo.com - October 17 at 6:36 PM
Diffusion Pharmaceuticals to Present at the 2017 BIO Investor ForumDiffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum
finance.yahoo.com - October 10 at 3:34 PM
Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?Is It The Right Time To Buy Diffusion Pharmaceuticals Inc (DFFN)?
finance.yahoo.com - September 14 at 12:13 AM
DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017DFFN: Phase 3 Trial of TSC in GBM to Initiate Before End of 2017
finance.yahoo.com - August 31 at 5:44 PM
Diffusion Pharmaceuticals Names William Hornung Chief Business OfficerDiffusion Pharmaceuticals Names William Hornung Chief Business Officer
finance.yahoo.com - August 23 at 8:00 PM
Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business UpdateDiffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 14 at 6:10 PM
RestorGenex Corp. (NASDAQ:DFFN) Scheduled to Post Quarterly Earnings on MondayRestorGenex Corp. (NASDAQ:DFFN) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 7 at 10:28 AM
Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain CancerDiffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer
finance.yahoo.com - August 3 at 11:41 AM

SEC Filings

RestorGenex (NASDAQ:DFFN) SEC Filings

DateFilerForm TypeView

Social Media

Financials

RestorGenex (NASDAQ:DFFN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

RestorGenex (NASDAQ DFFN) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.